Portfolio Holdings Detail for ISIN IE00BF4RFH31
| Stock Name / Fund | iShares MSCI World Small Cap UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares III Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300PZLRJB7M8H1057 |
| ETF Ticker | WSML(USD) LSE |
| ETF Ticker | WLDS(GBP) LSE |
| ETF Ticker | IUSN(EUR) F |
| ETF Ticker | IUSN.DE(EUR) CXE |
| ETF Ticker | WLDS.LS(GBP) CXE |
| ETF Ticker | WSML.LS(USD) CXE |
| ETF Ticker | WSML.L(GBP) LSE |
| ETF Ticker | WLDS.L(GBP) LSE |
Holdings detail for NVCR
| Stock Name | Novocure Ltd |
| Ticker | NVCR(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | JE00BYSS4X48 |
| LEI | 213800YPP55UMHWA4826 |
Show aggregate NVCR holdings
News associated with NVCR
- NovoCure (NASDAQ:NVCR) Shares Gap Up Following Insider Buying Activity
- Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) gapped up before the market opened on Monday following insider buying activity. The stock had previously closed at $12.28, but opened at $13.65. NovoCure shares last traded at $13.03, with a volume of 543,802 shares trading hands. Specifically, CEO Ashley Cordova acquired 81,550 shares of the […] - 2025-09-10 02:26:51
- Analysts Set NovoCure Limited (NASDAQ:NVCR) Price Target at $28.79
- Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average […] - 2025-08-21 04:44:51
- Novocure Submits Premarket Approval Application To FDA For TTFields Therapy In Pancreatic Cancer
- (RTTNews) - Novocure (NVCR) Wednesday said it has submitted a premarket approval application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. - 2025-08-20 08:50:20
- TD Asset Management Inc Sells 204,942 Shares of NovoCure Limited (NASDAQ:NVCR)
- TD Asset Management Inc decreased its position in NovoCure Limited (NASDAQ:NVCR – Free Report) by 81.0% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 48,212 shares of the medical equipment provider’s stock after selling 204,942 shares during the period. TD Asset Management Inc’s holdings in NovoCure […] - 2025-08-05 04:37:19
- Y Intercept Hong Kong Ltd Has $419,000 Stock Position in NovoCure Limited (NASDAQ:NVCR)
- Y Intercept Hong Kong Ltd raised its stake in NovoCure Limited (NASDAQ:NVCR – Free Report) by 25.2% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,492 shares of the medical equipment provider’s stock after buying an additional 4,723 shares during […] - 2025-07-29 05:56:52
- NovoCure (NASDAQ:NVCR) Receives “Equal Weight” Rating from Wells Fargo & Company
- Wells Fargo & Company reissued their equal weight rating on shares of NovoCure (NASDAQ:NVCR – Free Report) in a report released on Friday morning, Marketbeat reports. The firm currently has a $14.50 target price on the medical equipment provider’s stock, down from their previous target price of $40.00. Other analysts also recently issued reports about […] - 2025-07-28 04:18:52
- Bank of New York Mellon Corp Purchases 2,062 Shares of NovoCure Limited (NASDAQ:NVCR)
- Bank of New York Mellon Corp grew its position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 0.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 324,592 shares of the medical equipment provider’s stock after acquiring an […] - 2025-07-25 04:35:07
- 32,179 Shares in NovoCure Limited (NASDAQ:NVCR) Purchased by Jennison Associates LLC
- Jennison Associates LLC acquired a new position in NovoCure Limited (NASDAQ:NVCR – Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 32,179 shares of the medical equipment provider’s stock, valued at approximately $573,000. Several other large investors also […] - 2025-07-23 06:20:54
- Teacher Retirement System of Texas Acquires 3,123 Shares of NovoCure Limited (NASDAQ:NVCR)
- Teacher Retirement System of Texas raised its holdings in NovoCure Limited (NASDAQ:NVCR – Free Report) by 5.3% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 62,375 shares of the medical equipment provider’s stock after purchasing an additional 3,123 shares during the quarter. Teacher Retirement System of Texas’ holdings in NovoCure were worth […] - 2025-07-14 04:56:53
- LADENBURG THALM/SH SH Begins Coverage on NovoCure (NASDAQ:NVCR)
- LADENBURG THALM/SH SH began coverage on shares of NovoCure (NASDAQ:NVCR – Get Free Report) in a research report issued on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $30.00 price target on the medical equipment provider’s stock. LADENBURG THALM/SH SH’s price objective points to a potential upside of 64.93% from the […] - 2025-07-10 04:01:26
- California State Teachers Retirement System Sells 635 Shares of NovoCure Limited (NASDAQ:NVCR)
- California State Teachers Retirement System reduced its stake in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 0.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 96,389 shares of the medical equipment provider’s stock after selling 635 shares during the quarter. California […] - 2025-06-06 05:42:57
- NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Brokerages
- Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month […] - 2025-06-04 03:06:44
- BNP Paribas Financial Markets Sells 147,371 Shares of NovoCure Limited (NASDAQ:NVCR)
- BNP Paribas Financial Markets decreased its position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 83.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 28,555 shares of the medical equipment provider’s stock after selling 147,371 shares during the period. BNP Paribas Financial Markets’ holdings in NovoCure were worth $851,000 as of […] - 2025-05-22 04:38:53
- NovoCure Limited (NASDAQ:NVCR) Shares Acquired by Deutsche Bank AG
- Deutsche Bank AG lifted its stake in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 20.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 194,327 shares of the medical equipment provider’s stock after acquiring an additional 33,293 shares during the quarter. Deutsche Bank […] - 2025-05-19 05:06:55
- Tower Research Capital LLC TRC Sells 6,669 Shares of NovoCure Limited (NASDAQ:NVCR)
- Tower Research Capital LLC TRC trimmed its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 76.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,034 shares of the medical equipment provider’s stock after selling 6,669 shares […] - 2025-05-12 04:50:52
- NovoCure (NASDAQ:NVCR) and Meihua International Medical Technologies (NASDAQ:MHUA) Head to Head Survey
- Meihua International Medical Technologies (NASDAQ:MHUA – Get Free Report) and NovoCure (NASDAQ:NVCR – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations and valuation. Institutional and Insider Ownership 1.2% of […] - 2025-05-06 02:09:04
- Why NovoCure Stock Skyrocketed This Week
- Shares of NovoCure (NASDAQ: NVCR) are edging higher on Thursday. The company's stock gained 0.11% as of 3:30 p.m. ET after fluctuating between gains and losses throughout the session. This muted reaction comes as the S&P 500 gained 0.3% and the Nasdaq Composite rose 0.6%. - 2025-04-25 14:21:57
- Bank of Montreal Can Acquires New Shares in NovoCure Limited (NASDAQ:NVCR)
- Bank of Montreal Can purchased a new position in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) in the fourth quarter, Holdings Channel.com reports. The firm purchased 8,183 shares of the medical equipment provider’s stock, valued at approximately $244,000. Other institutional investors have also made changes to their positions in the company. Tidal Investments LLC […] - 2025-04-25 05:08:56
- Piper Sandler Issues Pessimistic Forecast for NovoCure (NASDAQ:NVCR) Stock Price
- NovoCure (NASDAQ:NVCR – Get Free Report) had its price objective reduced by analysts at Piper Sandler from $42.00 to $34.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the medical equipment provider’s stock. Piper Sandler’s target price would indicate a potential upside of 83.29% from the stock’s current […] - 2025-04-25 04:31:12
- NovoCure (NASDAQ:NVCR) Lowered to Sell Rating by StockNews.com
- NovoCure (NASDAQ:NVCR – Get Free Report) was downgraded by StockNews.com from a “hold” rating to a “sell” rating in a research note issued on Friday. Other research analysts have also recently issued research reports about the stock. Piper Sandler reduced their price target on shares of NovoCure from $42.00 to $34.00 and set an “overweight” […] - 2025-04-25 03:10:53
- NovoCure Surpasses Q1 Expectations
- NovoCure (NASDAQ:NVCR), a leader in oncology treatments using Tumor Treating Fields (TTFields) therapy, released its first-quarter results on April 24, 2025. The company reported notable gains with revenue rising to $155 million (GAAP) in Q1 2025, surpassing Wall Street’s e - 2025-04-24 10:25:13
- Legal & General Group Plc Reduces Stake in NovoCure Limited (NASDAQ:NVCR)
- Legal & General Group Plc cut its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 14.5% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 157,758 shares of the medical equipment provider’s stock after selling 26,654 shares during the quarter. Legal & General Group Plc’s holdings in NovoCure were worth $4,701,000 […] - 2025-04-22 05:44:56
- Summit Investment Advisors Inc. Raises Stock Holdings in NovoCure Limited (NASDAQ:NVCR)
- Summit Investment Advisors Inc. boosted its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 6.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,141 shares of the medical equipment provider’s stock after acquiring an additional 708 shares […] - 2025-04-21 04:56:57
- StockNews.com Downgrades NovoCure (NASDAQ:NVCR) to Sell
- NovoCure (NASDAQ:NVCR – Get Free Report) was downgraded by stock analysts at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday. Other research analysts have also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and issued a $38.00 target price on shares […] - 2025-04-11 05:18:59
- Pictet Asset Management Holding SA Boosts Stake in NovoCure Limited (NASDAQ:NVCR)
- Pictet Asset Management Holding SA boosted its holdings in shares of NovoCure Limited (NASDAQ:NVCR – Free Report) by 19.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 14,919 shares of the medical equipment provider’s stock after acquiring an additional […] - 2025-04-10 05:37:15
- 21,600 Shares in NovoCure Limited (NASDAQ:NVCR) Purchased by KLP Kapitalforvaltning AS
- KLP Kapitalforvaltning AS acquired a new stake in NovoCure Limited (NASDAQ:NVCR – Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 21,600 shares of the medical equipment provider’s stock, valued at approximately $644,000. A number of other hedge funds have also modified their holdings of […] - 2025-04-02 05:16:54
- NovoCure Limited (NASDAQ:NVCR) Receives $35.80 Consensus PT from Analysts
- Shares of NovoCure Limited (NASDAQ:NVCR – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the five brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective […] - 2025-03-24 04:40:48
- NovoCure (NASDAQ:NVCR) Raised to “Hold” at StockNews.com
- NovoCure (NASDAQ:NVCR – Get Free Report) was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Tuesday. Other analysts have also issued reports about the stock. Wedbush reissued a “neutral” rating and set a $29.00 target price on shares of NovoCure in a […] - 2025-03-20 03:44:55
- Charles Schwab Investment Management Inc. Purchases 11,771 Shares of NovoCure Limited (NASDAQ:NVCR)
- Charles Schwab Investment Management Inc. boosted its position in NovoCure Limited (NASDAQ:NVCR – Free Report) by 1.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 836,214 shares of the medical equipment provider’s stock after buying an additional 11,771 shares during the period. […] - 2025-03-19 05:52:57
- SBI Securities Co. Ltd. Invests $70,000 in NovoCure Limited (NASDAQ:NVCR)
- SBI Securities Co. Ltd. acquired a new position in NovoCure Limited (NASDAQ:NVCR – Free Report) during the fourth quarter, HoldingsChannel.com reports. The fund acquired 2,341 shares of the medical equipment provider’s stock, valued at approximately $70,000. Several other institutional investors have also added to or reduced their stakes in the stock. Brooklyn Investment Group bought […] - 2025-03-10 06:07:07
iShares MSCI World Small Cap UCITS ETF USD (Acc) NVCR holdings
| Date | Number of NVCR Shares Held | Base Market Value of NVCR Shares | Local Market Value of NVCR Shares | Change in NVCR Shares Held | Change in NVCR Base Value | Current Price per NVCR Share Held | Previous Price per NVCR Share Held |
|---|
| 2025-11-27 (Thursday) | 81,746 | USD 1,043,079 | USD 1,043,079 | 0 | USD 0 | USD 12.76 | USD 12.76 |
| 2025-11-26 (Wednesday) | 81,746 | USD 1,043,079 | USD 1,043,079 | -159 | USD 7,800 | USD 12.76 | USD 12.64 |
| 2025-11-25 (Tuesday) | 81,905 | USD 1,035,279 | USD 1,035,279 | 0 | USD 9,009 | USD 12.64 | USD 12.53 |
| 2025-11-24 (Monday) | 81,905 | USD 1,026,270 | USD 1,026,270 | 0 | USD 47,505 | USD 12.53 | USD 11.95 |
| 2025-11-21 (Friday) | 81,905 | USD 978,765 | USD 978,765 | 0 | USD 40,134 | USD 11.95 | USD 11.46 |
| 2025-11-20 (Thursday) | 81,905 | USD 938,631 | USD 938,631 | 525 | USD 6,830 | USD 11.46 | USD 11.45 |
| 2025-11-19 (Wednesday) | 81,380 | USD 931,801 | USD 931,801 | 5,280 | USD 60,456 | USD 11.45 | USD 11.45 |
| 2025-11-18 (Tuesday) | 76,100 | USD 871,345 | USD 871,345 | 0 | USD 13,698 | USD 11.45 | USD 11.27 |
| 2025-11-17 (Monday) | 76,100 | USD 857,647 | USD 857,647 | 0 | USD -3,805 | USD 11.27 | USD 11.32 |
| 2025-11-14 (Friday) | 76,100 | USD 861,452 | USD 861,452 | -636 | USD -11,804 | USD 11.32 | USD 11.38 |
| 2025-11-13 (Thursday) | 76,736 | USD 873,256 | USD 873,256 | 0 | USD 1,535 | USD 11.38 | USD 11.36 |
| 2025-11-12 (Wednesday) | 76,736 | USD 871,721 | USD 871,721 | 0 | USD -38,368 | USD 11.36 | USD 11.86 |
| 2025-11-11 (Tuesday) | 76,736 | USD 910,089 | USD 910,089 | 0 | USD 45,274 | USD 11.86 | USD 11.27 |
| 2025-11-10 (Monday) | 76,736 | USD 864,815 | USD 864,815 | 0 | USD 26,858 | USD 11.27 | USD 10.92 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of NVCR by Blackrock for IE00BF4RFH31
Show aggregate share trades of NVCR| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-11-26 | SELL | -159 | 12.820 | 12.525 | 12.554 | USD -1,996 | 17.53 Profit of 790 on sale |
| 2025-11-26 | SELL | -159 | 12.820 | 12.525 | 12.554 | USD -1,996 | 17.53 Profit of 790 on sale |
| 2025-11-20 | BUY | 525 | | | 11.460* | | 17.62 |
| 2025-11-19 | BUY | 5,280 | | | 11.450* | | 17.65 |
| 2025-11-14 | SELL | -636 | 11.665 | 11.200 | 11.246 | USD -7,153 | 17.74 Profit of 4,129 on sale |
| 2025-10-29 | BUY | 314 | 13.480 | 13.705 | 13.682 | USD 4,296 | 18.08 |
| 2025-10-21 | BUY | 628 | 14.130 | 14.570 | 14.526 | USD 9,122 | 18.21 |
| 2025-10-07 | BUY | 314 | 14.160 | 14.620 | 14.574 | USD 4,576 | 18.27 |
| 2025-09-08 | SELL | -632 | 12.600 | 13.670 | 13.563 | USD -8,572 | 18.51 Profit of 3,124 on sale |
| 2025-08-15 | BUY | 314 | 11.730 | 11.860 | 11.847 | USD 3,720 | 18.54 |
| 2025-08-07 | BUY | 942 | 11.510 | 11.520 | 11.519 | USD 10,851 | 18.62 |
| 2025-07-29 | BUY | 314 | 11.375 | 11.950 | 11.892 | USD 3,734 | 18.86 |
| 2025-07-14 | BUY | 620 | 17.420 | 17.760 | 17.726 | USD 10,990 | 18.98 |
| 2025-06-30 | BUY | 620 | 17.800 | 18.700 | 18.610 | USD 11,538 | 19.03 |
| 2025-06-25 | BUY | 930 | 17.325 | 17.350 | 17.348 | USD 16,133 | 19.06 |
| 2025-06-20 | SELL | -156 | 16.690 | 17.070 | 17.032 | USD -2,657 | 19.10 Profit of 323 on sale |
| 2025-06-12 | SELL | -1,248 | 18.200 | 18.330 | 18.317 | USD -22,860 | 19.17 Profit of 1,059 on sale |
| 2025-06-02 | BUY | 468 | 17.040 | 19.110 | 18.903 | USD 8,847 | 19.28 |
| 2025-05-28 | BUY | 312 | 19.370 | 19.425 | 19.419 | USD 6,059 | 19.28 |
| 2025-05-14 | BUY | 155 | 17.100 | 18.110 | 18.009 | USD 2,791 | 19.37 |
| 2025-05-13 | BUY | 310 | 18.140 | 18.850 | 18.779 | USD 5,821 | 19.38 |
| 2025-05-07 | BUY | 468 | 16.650 | 16.715 | 16.709 | USD 7,820 | 19.44 |
| 2025-04-28 | BUY | 155 | 18.310 | 19.020 | 18.949 | USD 2,937 | 19.54 |
| 2025-04-16 | BUY | 2,028 | 15.830 | 16.280 | 16.235 | USD 32,925 | 19.74 |
| 2025-04-14 | BUY | 312 | 16.550 | 17.055 | 17.005 | USD 5,305 | 19.80 |
| 2025-04-08 | SELL | -312 | 15.370 | 17.190 | 17.008 | USD -5,306 | 19.94 Profit of 914 on sale |
| 2025-04-04 | SELL | -314 | 16.490 | 16.800 | 16.769 | USD -5,265 | 20.00 Profit of 1,016 on sale |
| 2025-03-28 | BUY | 1,560 | 18.860 | 18.930 | 18.923 | USD 29,520 | 20.08 |
| 2025-03-12 | SELL | -312 | 20.620 | 21.550 | 21.457 | USD -6,695 | 20.18 Loss of -399 on sale |
| 2025-03-04 | SELL | -312 | 18.190 | 18.450 | 18.424 | USD -5,748 | 20.20 Profit of 554 on sale |
| 2025-02-26 | SELL | -620 | 21.960 | 22.300 | 22.266 | USD -13,805 | 20.23 Loss of -1,264 on sale |
| 2025-02-13 | BUY | 157 | 21.710 | 21.820 | 21.809 | USD 3,424 | 20.01 |
| 2025-02-12 | BUY | 628 | 21.370 | 21.400 | 21.397 | USD 13,437 | 19.99 |
| 2025-01-27 | BUY | 154 | 25.380 | 26.360 | 26.262 | USD 4,044 | 19.15 |
| 2025-01-23 | BUY | 154 | 27.020 | 27.320 | 27.290 | USD 4,203 | 18.87 |
| 2024-12-09 | BUY | 5,580 | 28.650 | 28.820 | 28.803 | USD 160,721 | 18.30 |
| 2024-12-04 | BUY | 308 | 29.230 | 31.283 | 31.078 | USD 9,572 | 17.68 |
| 2024-12-03 | BUY | 471 | 30.510 | 32.600 | 32.391 | USD 15,256 | 17.40 |
| 2024-11-19 | BUY | 954 | 16.480 | 16.550 | 16.543 | USD 15,782 | 16.76 |
| 2024-11-18 | BUY | 318 | 15.730 | 16.160 | 16.117 | USD 5,125 | 16.79 |
| 2024-11-12 | BUY | 628 | 17.820 | 18.380 | 18.324 | USD 11,507 | 16.76 |
| 2024-11-11 | BUY | 157 | 18.190 | 18.210 | 18.208 | USD 2,859 | 16.66 |
| 2024-11-11 | BUY | 157 | 18.190 | 18.210 | 18.208 | USD 2,859 | 16.66 |
| 2024-11-07 | BUY | 780 | 17.650 | 18.100 | 18.055 | USD 14,083 | 16.53 |
| 2024-11-07 | BUY | 780 | 17.650 | 18.100 | 18.055 | USD 14,083 | 16.53 |
| 2024-10-23 | BUY | 312 | 16.180 | 16.200 | 16.198 | USD 5,054 | 16.21 |
| 2024-10-23 | BUY | 312 | 16.180 | 16.200 | 16.198 | USD 5,054 | 16.21 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of NVCR
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 146,296 | 0 | 421,759 | 34.7% |
| 2025-09-18 | 109,188 | 0 | 560,456 | 19.5% |
| 2025-09-17 | 119,469 | 301 | 498,067 | 24.0% |
| 2025-09-16 | 191,175 | 400 | 705,469 | 27.1% |
| 2025-09-15 | 272,067 | 0 | 1,107,083 | 24.6% |
| 2025-09-12 | 109,857 | 0 | 270,874 | 40.6% |
| 2025-09-11 | 218,116 | 0 | 689,642 | 31.6% |
| 2025-09-10 | 230,953 | 95 | 658,890 | 35.1% |
| 2025-09-09 | 234,044 | 4,681 | 645,307 | 36.3% |
| 2025-09-08 | 339,725 | 3,440 | 815,445 | 41.7% |
| 2025-09-05 | 166,892 | 0 | 408,146 | 40.9% |
| 2025-09-04 | 257,672 | 43,716 | 678,816 | 38.0% |
| 2025-09-03 | 177,114 | 0 | 351,319 | 50.4% |
| 2025-09-02 | 137,400 | 0 | 404,389 | 34.0% |
| 2025-08-29 | 160,727 | 0 | 352,263 | 45.6% |
| 2025-08-28 | 191,578 | 3,553 | 657,423 | 29.1% |
| 2025-08-27 | 150,551 | 7,255 | 425,992 | 35.3% |
| 2025-08-26 | 119,516 | 0 | 645,276 | 18.5% |
| 2025-08-25 | 171,812 | 0 | 553,315 | 31.1% |
| 2025-08-22 | 94,300 | 0 | 476,262 | 19.8% |
| 2025-08-21 | 143,620 | 0 | 367,651 | 39.1% |
| 2025-08-20 | 190,862 | 110 | 434,326 | 43.9% |
| 2025-08-19 | 137,859 | 0 | 457,522 | 30.1% |
| 2025-08-18 | 179,056 | 0 | 473,961 | 37.8% |
| 2025-08-15 | 169,569 | 8 | 564,351 | 30.0% |
| 2025-08-14 | 212,081 | 0 | 504,691 | 42.0% |
| 2025-08-13 | 268,074 | 0 | 1,199,258 | 22.4% |
| 2025-08-12 | 212,713 | 4,365 | 614,711 | 34.6% |
| 2025-08-11 | 194,203 | 4 | 512,173 | 37.9% |
| 2025-08-08 | 254,996 | 1,239 | 736,775 | 34.6% |
| 2025-08-07 | 243,762 | 608 | 804,784 | 30.3% |
| 2025-08-06 | 229,740 | 3,802 | 734,190 | 31.3% |
| 2025-08-05 | 463,496 | 1,061 | 2,536,451 | 18.3% |
| 2025-08-04 | 323,993 | 53 | 954,167 | 34.0% |
| 2025-08-01 | 378,472 | 0 | 1,053,485 | 35.9% |
| 2025-07-31 | 479,008 | 2,516 | 1,888,144 | 25.4% |
| 2025-07-30 | 452,345 | 0 | 1,441,401 | 31.4% |
| 2025-07-29 | 329,608 | 1,502 | 1,070,202 | 30.8% |
| 2025-07-28 | 306,605 | 0 | 1,104,404 | 27.8% |
| 2025-07-25 | 533,024 | 42,563 | 1,609,831 | 33.1% |
| 2025-07-24 | 763,758 | 71,574 | 2,115,331 | 36.1% |
| 2025-07-23 | 145,473 | 921 | 417,907 | 34.8% |
| 2025-07-22 | 113,998 | 0 | 328,855 | 34.7% |
| 2025-07-21 | 140,312 | 0 | 474,581 | 29.6% |
| 2025-07-18 | 96,636 | 400 | 339,936 | 28.4% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.